
|Videos|January 30, 2023
The Role of Ruxolitinib in Myelofibrosis Treatment
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5




























